MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

ArriVent BioPharma, Inc. - Common Stock (NQ:AVBP)

22.13 +0.96 (+4.53%)
Streaming Delayed Price Updated: 2:52 PM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about ArriVent BioPharma, Inc. - Common Stock

News headline image
ArriVent Posts Wider Loss in Fiscal Q2 ↗
Via The Motley Fool
Topics Intellectual Property
News headline image
Centene, BrightView Holdings, ArriVent BioPharma And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
ArriVent Lead Drug Candidate Shows Promise In Lung Cancer Type, Analyst Sees Over 50% Upside ↗
B. Riley initiates coverage on ArriVent Biopharma, citing firmonertinib's potential in NSCLC. The analyst sees strong upside with a $37 price target. 
Via Benzinga
News headline image
This Microsoft Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗
 
Via Benzinga
News headline image
Why Logility Supply Chain Solutions Shares Are Trading Higher By Over 23%; Here Are 20 Stocks Moving Premarket ↗
 
Via Benzinga
Topics Economy
News headline image
Discover the 3 Best-Performing Biotech IPO Stocks of 2024
Check out which three biotechnology companies that went public in 2024 and are performing the best and a big factor influenced their rise. 
Via MarketBeat
Topics Initial Public Offering
News headline image
AVBP Stock Earnings: ArriVent BioPharma Misses EPS for Q2 2024 ↗
AVBP stock results show that ArriVent BioPharma missed analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
News headline image
Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million ↗
Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent... 
Via Talk Markets
News headline image
AVBP Stock Earnings: ArriVent BioPharma Beats EPS for Q1 2024 ↗
AVBP stock results show that ArriVent BioPharma beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
News headline image
ProfoundBio Discovers The Joys Of Having A Wealthy Owner ↗
Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The deal is the fourth acquisition of a China-related innovative drugmaker by a... 
Via Benzinga
News headline image
Week In Review: AriBio Sells China Rights To Alzheimer’s Candidate In $770 Million Deal ↗
South Korea’s AriBio out-licensed China rights for AR1001, an Alzheimer’s disease candidate, in an agreement worth up to $770 million. The company acquiring the asset asked to remain anonymous because... 
Via Talk Markets
News headline image
$10M Bet On ArriVent BioPharma? Check Out These 4 Stocks Insiders Are Buying ↗
Although U.S. stocks closed higher on Thursday, there were a few notable insider trades. 
Via Benzinga
News headline image
KKR-Backed BrightSpring Prices Below Expectations, Then Opens Lower ↗
Health-care services provider BrightSpring, which is backed by private equity firm KKR, priced its initial public offering at $13, below a marketed range of $15 to $18 per share, before opening on... 
Via Talk Markets
Topics Initial Public Offering
News headline image
Week In Review: Arrivent BioPharma Raises $175 Million In IPO For In-Licensings From China ↗
ArriVent BioPharma priced its upsized Nasdaq IPO at $18 dollars per share, raising $175 million. The company’s stated goal is to find promising novel assets from China and other countries, which it... 
Via Talk Markets
Topics Initial Public Offering
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story